Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats

European Journal of Pharmacology

Volumn 600, Issue 1-3, 2008, Pages 78-82

  Jin, Feng ^a   Wu, Qin ^b   Lu, Yuan Fu ^a   Gong, Qi Hai ^a   Shi, Jing Shan ^a,b  

^a ZUNYI MEDICAL UNIVERSITY   (China)

^b The Key Laboratory of Basic Pharmacology of Guizhou Province   (China)

Author keywords

(Rat); 6 OHDA 6 hydroxydopamine ; Inflammation; Parkinson's disease; Resveratrol

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; OXIDOPAMINE; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHROMATIN CONDENSATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG DOSE COMPARISON; HISTOPATHOLOGY; MALE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MALE; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STILBENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56149119401     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.005     Document Type: Article

References (34)

1. Carman L.S., Gage F.H., and Shults C.W. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res. 553 (1991) 275-283
2. Chen H., Zhang S.M., Hernán M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60 (2003) 1059-1064
3. Donnelly L.E., Newton R., Kennedy G.E., Fenwick P.S., Leung R.H., Ito K., Russell R.E., and Barnes P.J. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am. J. Physiol., Lung Cell. Mol. Physiol. 287 (2004) L774-L783
4. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., and Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 205 (2007) 295-312
5. Gao H.M., and Hong J.S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 29 (2008) 357-365
6. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., and Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81 (2002) 1285-1297
7. Gélinas S., and Martinoli M.G. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J. Neurosci. Res. 70 (2002) 90-96
8. Granados-Soto V. Pleiotropic effects of resveratrol. Drug News Perspect. 16 (2003) 299-307
9. Håkansson A., Bergman O., Chrapkowska C., Westberg L., Belin A.C., Sydow O., Johnels B., Olson L., Holmberg B., and Nissbrandt H. Cyclooxygenase-2 polymorphisms in Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144 (2007) 367-369
10. Hunter R.L., Dragicevic N., Seifert K., Choi D.Y., Liu M., Kim H.C., Cass W.A., Sullivan P.G., and Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem. 100 (2007) 1375-1386
11. Kang J.M., Park H.J., Choi Y.G., Choe I.H., Park J.H., Kim Y.S., and Lim S. Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model. Brain Res. 1131 (2007) 211-219
12. Kim Y.A., Lim S.Y., Rhee S.H., Park K.Y., Kim C.H., Choi B.T., Lee S.J., Park Y.M., and Choi Y.H. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells. Int. J. Mol. Med. 17 (2006) 1069-1075
13. Klivenyi P., Gardian G., Calingasan N.Y., Yang L., and Beal M.F. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Mol. Neurosci. 21 (2003) 191-198
14. Koprich J.B., Reske-Nielsen C., Mithal P., and Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J. Neuroinflammation. 5 (2008) 8-20
15. Kundu J.K., Shin Y.K., Kim S.H., and Surh Y.J. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 27 (2006) 1465-1674
16. Kuwano T., Nakao S., Yamamoto H., Tsuneyoshi M., Yamamoto T., Kuwano M., and Ono M. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 18 (2004) 300-310
17. Lee C.S., Sauer H., and Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 72 (1996) 641-653
18. Liang X., Wu L., Wang Q., Hand T., Bilak M., McCullough L., and Andreasson K. Function of COX-2 and prostaglandins in neurological disease. J. Mol. Neurosci. 33 (2007) 94-99
19. Martín A.R., Villegas I., Sánchez-Hidalgo M., and de la Lastra C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 147 (2006) 873-885
20. Murias M., Handler N., Erker T., Pleban K., Ecker G., Saiko P., Szekeres T., and Jäger W. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem. 12 (2004) 5571-5578
21. O'Banion M.K. COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. Expert Opin. Investig. Drugs 8 (1999) 1521-1536
22. Orr C.F., Rowe D.B., and Halliday G.M. An inflammatory review of Parkinson's disease. Prog. Neurobiol. 68 (2002) 325-340
23. Reksidler A.B., Lima M.M., Zanata S.M., Machado H.B., da Cunha C., Andreatini R., Tufik S., and Vital M.A. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur. J. Pharmacol. 560 (2007) 163-175
24. Sinha K., Chaudhary G., and Gupta Y.K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 71 (2002) 655-665
25. Skaper S.D. The brain as a target for inflammatory processes and neuroprotective strategies. Ann. N.Y. Acad. Sci. 1122 (2007) 23-34
26. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5473-5478
27. Tweardy D.J., Glazer E.W., Mott P.L., and Anderson K. Modulation by tumor necrosis factor-alpha of human astroglial cell production of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF). J. Neuroimmunol. 32 (1991) 269-278
28. Tweedie D., Sambamurti K., and Greig N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res. 4 (2007) 378-385
29. Tyurina Y.Y., Kapralov A.A., Jiang J., Borisenko G.G., Potapovich A.I., Sorokin A., Kochanek P.M., Graham S.H., Schor N.F., and Kagan V.E. Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells. Brain Res. 1093 (2006) 71-82
30. Vijitruth R., Liu M., Choi D.Y., Nguyen X.V., Hunter R.L., and Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation 3 (2006) 6-21
31. Wahner A.D., Bronstein J.M., Bordelon Y.M., and Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69 (2007) 1836-1842
32. Wang T., Pei Z., Zhang W., Liu B., Langenbach R., Lee C., Wilson B., Reece J.M., Miller D.S., and Hong J.S. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J. 19 (2005) 1134-1136
33. Zhang K., Tarazi F.I., Davids E., and Baldessarini R.J. Plasticity of dopamine D4 receptors in rat forebrain: temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning. Neuropsychopharmacology 26 (2002) 625-633
34. Zhou F., Wu J.Y., Sun X.L., Yao H.H., Ding J.H., and Hu G. Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 32 (2007) 2570-2580